Dec. 4, 2019 Price forecast | 2 weeks: -5.97% | 1 month: -10.31% | 3 months: -9.39%


DNLI stock forecast

Our latest prediction for Denali Therapeutics, Inc.'s stock price was made on the Dec. 4, 2019 when the stock price was at 18.16$.

In the short term (2weeks), DNLI's stock price should underperform the market by -5.97%. During that period the price should oscillate between -8.79% and +7.06%.

In the medium term (3months), DNLI's stock price should underperform the market by -9.39%. During that period the price should oscillate between -27.97% and +15.62%.


About Denali Therapeutics, Inc.

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

At the moment the company generates 148M USD in revenues.

On its last earning announcement, the company reported a loss of -0.65$ per share.

The book value per share is 5.17$

Denali Therapeutics, Inc. website


Three months stock forecastDec. 4, 2019


Financials

Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
148M - -81M -54.60% -66M -0.65 - - 95M 5.17 -11M -17M -27M